Mutations in KIF11 cause autosomal dominant microcephaly variably associated with congenital lymphedema and chorioretinopathy

Pia Ostergaard,¹ Michael A Simpson,² Antonella Mendola,³ Pradeep Vasudevan,⁴ Fiona C Connell,⁵ Andreas van Impel,⁶ Anthony T Moore,⁷ Bart L Loeys,⁸ Arash Ghalamkarpour,⁹ Alexandros Onoufriadis,² Ines Martinez-Corral,⁹ Sophie Devery,¹⁰ Jules G Leroy,¹¹ Lut van Laer,⁸ Amihood Singer,¹² Martin G Bialer,¹³ Meriel McEntagart,¹⁴ Oliver Quarrell,¹⁵ Glen Brice,¹⁴ Richard C Trembath,² Stefan Schulte-Merker,⁶ Taija Makinen,⁹ Miikka Vikkula,³,¹⁶ Peter S Mortimer,¹⁷ Sahar Mansour,¹⁴ and Steve Jeffery,¹

¹ Medical Genetics Unit, Biomedical Sciences, St George's University of London, London SW17 0RE, UK.
² Division of Genetics and Molecular Medicine, King's College London School of Medicine, Guy's Hospital, London SE1 9RT, UK.
³ Laboratory of Human Molecular Genetics, de Duve Institute, Université catholique de Louvain, B-1200 Brussels, Belgium.
⁴ Clinical Genetics, University Hospitals of Leicester NHS Trust, Leicester Royal Infirmary, Leicester LE1 5WW, UK.
⁵ Clinical Genetics, Guy's and St Thomas' NHS Foundation Trust, Guy's Hospital, London SE1 9RT, UK.
⁶ Hubrecht Institute-KNAW & UMC, 3584 CT Utrecht, Netherlands.
⁷ UCL Institute of Ophthalmology, Moorfields Eye Hospital and Hospital for Children, London EC1V 2PD, UK.
⁸ Center for Medical Genetics, Antwerp University Hospital and University of Antwerp, B-2650 Antwerp, Belgium.
⁹ Lymphatic Development Laboratory, Cancer Research UK London Research Institute, London WC2A 3PX, UK.
¹⁰ Moorfields Eye Hospital NHS Foundation Trust, London EC1V 2PD, UK.
¹¹ C. Hooft Children's Hospital, Ghent University Hospital, B-9000 Ghent, Belgium.
¹² Pediatrics and Medical Genetics, Barzilai Medical Center, 78306 Ashkelon, Israel.
¹³ Division of Medical Genetics, North Shore LIJ Health System, Manhasset, NY 11030, USA.
¹⁴ South West Thames Regional Genetics Service, St. George's University of London, London SW17 0RE, UK.
¹⁵ Sheffield Clinical Genetics Service, Sheffield Children's Hospital, Sheffield S10 2TH, UK
¹⁶ Walloon Excellence in Lifesciences and Biotechnology (WELBIO), Université catholique de Louvain, B-1200 Brussels, Belgium.
¹⁷ Department of Cardiac and Vascular Sciences, St George's University of London, London SW17 0RE, UK.

*Correspondence to be addressed to Steve Jeffery (sggt100@sgul.ac.uk)
We have identified KIF11 mutations in individuals with syndromic autosomal dominant microcephaly associated with lymphedema and/or chorioretinopathy. Initial whole exome sequencing revealed heterozygous KIF11 mutations in three individuals with a combination of microcephaly and lymphedema from a Microcephaly-Lymphedema-Chorioretinal Dysplasia (MLCRD) cohort. Subsequent Sanger sequencing of KIF11 in a further 15 unrelated microcephalic probands with lymphedema and/or chorioretinopathy identified additional heterozygous mutations in 12 of them. KIF11 encodes EG5, a homotetramer kinesin motor. The variety of mutations we have found (two nonsense, two splice site, four missense, and six indels causing frameshifts) are all predicted to have impact on the protein function. EG5 has previously been shown to play a role in spindle assembly and function and these findings highlight the critical role of proteins necessary for spindle formation in central nervous system development. Moreover, identification of KIF11 mutations in patients with chorioretinopathy and lymphedema suggests a previously undescribed involvement of EG5 in the development and maintenance of retinal and lymphatic structures.
There is substantial phenotypic overlap between microcephaly, primary lymphedema and chorioretinal dysplasia syndrome (MLCRD, MIM 152950) and chorioretinal dysplasia, microcephaly and mental retardation syndrome (CDMMR, MIM 156590). Both have been observed to segregate with autosomal dominant inheritance and present with an overlapping, yet variable, spectrum of central nervous system (CNS) and ocular developmental anomalies. Microcephaly, ranging from mild to severe, is the critical component of both syndromes and is often associated with mild to moderate developmental delay and a characteristic facial phenotype. Chorioretinopathy constitutes the most common eye abnormality, however, retinal folds, microphthalmia and myopic and hypermetropic astigmatism have also been reported and some individuals have no overt ocular phenotype. The presence of lymphedema has historically been seen as the critical differentiating feature between the two syndromes. The lymphedema in MLCRD is congenital, typically confined to the dorsum of the feet and lymphoscintigraphy reveals the absence of uptake from the web spaces between the toes. We have identified causative variants for this complex disease and show that MLCRD and CDMMR can be caused by mutation of KIF11, suggesting that both syndromes should be considered as a single entity with variable clinical features but a unified molecular basis.

Whole exome sequencing has proved to be a successful approach to the identification of causative mutations in primary lymphoedema. We therefore sought to establish the molecular genetic basis of MLCRD with whole exome sequencing of five unrelated probands with microcephaly and lymphedema (individuals MLCRD01:II-2, MLCRD02:II-2, MLCRD03:III-2, MLCRD04:I-1 and MLCRD05:I-1 in Table 1 and Table S1). Subjects for this study were recruited through genetic, lymphovascular and ophthalmic clinics in Europe. Informed consent was obtained from all subjects. All affected individuals and family members underwent a detailed physical examination. Ethical approval for this study was obtained from the South West London Research Ethics Committee (REC Ref: 05/Q0803/257 'Analysis of genes and their functions in patients with primary lymphoedema').

Whole exome capture was performed by in-solution hybridisation followed by massively parallel sequencing using the SureSelect All Exon CCDS Target Enrichment System (Agilent) and sequencing on a Genome AnalyserIIx (Illumina) with 76bp paired end reads. Sequence reads were aligned to the reference genome (hg18) with Novoalign (Novocraft Technologies SdnBhd). Duplicate reads, resulting from PCR clonality or optical duplicates, and reads mapping to multiple locations were excluded from downstream analysis. Depth and breadth of sequence coverage was calculated with custom scripts and the BedTools package. Over 5.1 gigabases of sequence was generated for each subject, such that >75% of the coding bases of the CCDS defined exome were represented by at least 20 reads (Table S2). Single nucleotide substitutions and small insertion/deletion variants were identified and quality filtered within the
SamTools software package\textsuperscript{11} and in-house software tools (Table S3). Variants were annotated with respect to genes and transcripts with the Annovar tool.\textsuperscript{13} Filtering of variants for novelty was performed by comparison to dbSNP132 and 1000 Genomes SNP calls (December 2010) and variants identified in 250 control exomes, primarily of European origin, sequenced and analyzed by the same method described above.

Analysis of the exome variant profiles was performed under a model of a rare autosomal dominant disorder, requiring at least one previously unobserved, heterozygous nonsynonymous or splice site substitution or an insertion or deletion in the same gene in all five individuals. This analysis failed to identify a single gene matching these criteria (Table S4). Further evaluation of the data with a prior expectation of genetic heterogeneity among these five cases revealed \textit{KIF11} as the only gene to harbour previously unobserved variants in three of the five individuals (Table S4). All three mutant alleles are predicted to lead to premature termination of the \textit{KIF11} protein product; a nonsense variant (p.R387X), a single nucleotide deletion (p.I1006LfsX62) and a dinucleotide deletion (p.L347EfsX8) (Table 1). All were confirmed by Sanger sequencing (primer sequences are listed in Table S5). Sequencing in the two subjects, in which exome sequencing did not reveal novel \textit{KIF11} variants, confirmed the wild-type coding sequence. Our findings indicated that heterozygous mutations of \textit{KIF11} underlie a significant proportion of MLCRD and we therefore assessed \textit{KIF11} for mutations in other MLCRD cases by Sanger sequencing in probands from nine additional kindreds, including a large multi-generational pedigree (MLCRD11, Figure S1). Sequencing revealed a further seven independent and novel \textit{KIF11} variants in a heterozygous state in those probands: three frameshift insertion and deletions, two missense substitutions, an acceptor splice site substitution and a donor splice site change that was observed in the proband from the multigenerational pedigree (Table 1). Each of the 10 identified novel \textit{KIF11} alleles was assessed in all available relatives: two were shown to have arisen \textit{de novo} and eight demonstrated cosegregation with microcephaly, variable in its severity, and a spectrum of eye and lymphatic abnormalities (Table 1). In total we identified \textit{KIF11} mutations in ten of the 14 MLCRD kindreds examined.

Within the extended MLCRD families, we observed individuals with heterozygous mutations in \textit{KIF11}, in whom there was no evidence of lymphatic involvement (Table 1). Given the considerable and recognised overlap between the two conditions, this led us to address the hypothesis that MLCRD and CDMMR are allelic disorders. Sequencing of \textit{KIF11} in a cohort of six independent kindreds in which microcephaly and eye abnormalities had been observed in the absence of lymphedema revealed five independent novel variants; two missense substitutions and three variants predicted to lead to premature termination of the protein product - including one nonsense mutation (p.R387X) that we had previously identified in pedigree MLCRD01 (Table 1). In total we identified 27 carriers of 14 novel mutant \textit{KIF11} alleles in 15
independent kindreds. None of the 14 variants is present in dbSNP, has been identified by the 1000 Genomes Project or was observed in a cohort of 250 control samples.

We failed to identify coding variation in *KIF11* in five kindreds, from which four probands had previously been diagnosed with MLCRD and one with CDMMR (Table S1). These cases may represent *KIF11* alleles comprising non-coding or undetected coding variants. They may represent phenocopies of MLCRD and CDMMR, or be explained by locus heterogeneity. We were unable to investigate the latter as none of the *KIF11* mutation negative families were of sufficient size to allow exclusion of the locus by linkage analysis.

*KIF11* encodes EG5, a bipolar, homotetrameric, slow processive plus-end-directed spindle motor protein of the kinesin-5 family. Each monomer contains a conserved N-terminal motor, a central coiled-coil domain and a C-terminal tail that contains a bimC box, a conserved sequence of positively charged amino acid residues (Figure 2). The homotetramer consists of four monomers that are arranged in an anti-parallel fashion so that the resulting molecule possesses two motor domains and two non-motor tails at each end of a central stalk. The contact of EG5 with microtubules is established through the C-terminal tails, while the subsequent sliding of the anti-parallel microtubules is driven by the motor domains. Seven of the identified mutant alleles are predicted to lead to premature termination of the protein; two nonsense and five frameshift, inducing insertions and deletions. A sixth frameshift variant, a single base deletion in the second to last exon, is predicted to result in substitution of the terminal 50 residues of the 1056 amino acid wild type protein and extension of the reading frame by a further 12 residues. The two splice site mutations are both predicted in HSF (Human Splicing Finder v.2.4.1) to have significant impact on splicing of the 5kb transcript (Table S6). The four missense mutations all alter evolutionarily conserved amino acid residues and are predicted to have a damaging effect on protein function according to SIFT and PolyPhen; three (p.F144L, p.R234C and p.S235C) are located within the motor domain and the fourth (p.R944C) is located within the bimC box in the C-terminal tail of the molecule (Figure S2).

*Kif11* has been shown to be widely expressed during murine embryonic development and is elevated in proliferating tissues. During zebrafish development *kif11* is dynamically expressed in tissues that are associated with rapid proliferation (Figure S3). Interestingly, homozygous disruption of *Kif11* leads to early embryonic lethality, with signs of a proliferation defect at embryonic day 2.5. It has been previously demonstrated that EG5 localizes to spindle microtubules during mitosis and also contributes to the assembly of the bipolar spindle, as well as regulating axonal outgrowth and CNS development. Several genes mutated in recessively inherited microcephaly have products with roles in centrosome formation and spindle development: *CENPJ, MCPH1, ASPM, CDK5RAP2, STIL, CEP152*, and *WDR62* (MIM: 608393, 251200, 608716, 604804, 612703, 604321 and 604317). Our identification of heterozygous
mutations in *KIF11* in dominant forms of microcephaly provides further evidence of the critical role of molecules involved in mitotic spindle function in CNS development. The observation of lymphedema and chorioretinopathy provides evidence for a previously undescribed role of EG5 in the development and maintenance of the lymphatic and retinal structures. It is currently unclear if MLCRD and CDMMR result from disruption of the mitotic function of EG5 or other roles of EG5 in the cell. The recently defined function of EG5 as a brake on microtubule activity as part of axonal turning\textsuperscript{22} provides the basis to speculate that the dominant mutations observed in this study may disrupt the control of lymphatic development in a similar manner.

Our findings demonstrate a pleiotropic phenotypic expression of mutant *KIF11* alleles and show that MLCRD and CDMMR are allelic disorders. Beyond the observed variability of lymphatic and eye involvement there is also a range in the severity of microcephaly. The microcephaly was primary (congenital) in all cases and there was some correlation between the degree of microcephaly and the severity of the learning disorder. Whilst all probands were ascertained by the presence of microcephaly, there was marked intra-familial variation (Table 1) including one parent with a normal head circumference, mild learning difficulties, no lymphedema and only a retinopathy associated with her diabetes (MLCRD02 I-1).

Chorioretinopathy was a highly specific finding in patients with mutations in *KIF11* but none of the patients had retinal folds or microphthalmia suggesting that the condition originally described by Jarmas et al\textsuperscript{5} might be non-allelic. A number of patients with additional abnormalities (e.g. thrombocytopenia, craniosynostosis) were not found to have mutations in *KIF11*. It could be of relevance for clinical differentiation that chorioretinopathy was not observed in any of the *KIF11* mutation negative cases (Table S1), although numbers are too small for this to be a definitive observation.

The lymphedema in the mutation positive cases was present at birth, restricted to both lower limbs and rarely extended above the knees. The dorsum of the feet was particularly involved with small, dysplastic nails and deep inter-phalangeal creases. There were often large calibre veins in the lower limbs. Clinically, the findings resemble those seen in Milroy disease (Figure 1D). The lymphedema was usually persistent but responded well to compression garments. Interestingly, there appeared to be some intra-familial consistency of the clinical features regardless of the type of mutation but this is difficult to verify with such small numbers.

In conclusion, we have identified *KIF11* mutations causative of autosomal dominant forms of microcephaly that are variably associated with congenital lymphedema and/or chorioretinopathy,
demonstrating that MLCRD and CDMMR are allelic disorders. The extreme variability of the phenotype, even between individuals with the same KIF11 mutation, suggests that there may be additional genetic or environmental factors that contribute to the extent of disruption. In addition, our findings also provide a substantial foundation for the existence of a previously undescribed link between EG5 and the development and maintenance of retinal and lymphatic structures. It remains to be elucidated how far the established mitotic function of EG5 can account for the different phenotypical aspects of MLCRD and CDMMR and whether at least some defects are consequences of a different role for EG5 during development.
Supplemental Data
Supplemental data include 6 tables and 3 figures.

Acknowledgements
This study has been made possible by the participation of the families concerned, and we are indebted to them. We would like to thank the clinicians involved: Dr Denise Williams (Birmingham Women's NHS Foundation Trust, Birmingham), and Dr Sixto Garcia Minaur (Hospital Universitario La Paz, Madrid). We would like to thank Dr Carolyn Moores (Crystallography, Birkbeck College, London) for advice on EG5 function, and Dr Anukampa Barth (University College, London) for help with documentation and analysis of the ISHs. This work was supported by British Heart Foundation (BHF) grants RG/08/006/25302, PG/10/58/28477 and FS/06/063/21445. The authors also acknowledge support from the Department of Health via the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award to Guy’s & St Thomas’ NHS Foundation Trust in partnership with King’s College London and King’s College Hospital NHS Foundation Trust, the specialist Biomedical Research Centre award for Ophthalmology to Moorfields Eye Hospital and the UCL Institute of Ophthalmology, the Sheffield Children’s Hospital charity, Marie Curie Fellowship and Cancer Research UK. These studies were also partially supported by the Interuniversity Attraction Poles initiated by the Belgian Federal Science Policy, network 6/05; Concerted Research Actions (A.R.C.) – Convention No 07/12-005 of the Belgian French Community Ministry; the F.R.S.-FNRS (Fonds de la Recherche Scientifique); and la Communauté française de Wallonie-Bruxelles and la Loterie nationale, Belgium. This research utilised the resources of the Biomics Centre, St George’s University of London and the Advanced Sequencing Facility, Cancer Research UK London Research Institute, with special thanks to Nik Matthews.

Web Resources
Online Mendelian Inheritance in man (OMIM), http://www.omim.org/
SIFT, http://sift.jcvi.org/
PolyPhen, http://genetics.bwh.harvard.edu/pph2/

Accession Numbers
The accession number for the KIF11 sequence reported in this paper is NM_004523.
References


FIGURE TITLES AND LEGENDS

Figure 1. Clinical features of KIF11 mutation positive patients with MLCRD and CDMMR

(A) Facial features of individuals diagnosed with MLCRD.
(B) Facial features of individuals diagnosed with CDMMR. The facies in (A) and (B) are characteristic with upslanting palpebral fissures, a broad nose with rounded tip, long philtrum with a thin upper lip, prominent chin and ears.
(C) Composite color photograph of left fundus in patient CDMMR05 II-1 showing focal areas of peripheral chorioretinal atrophy.
(D) Bilateral congenital lower limb primary lymphedema in cases with MLCRD, involving the dorsum of the feet with pitting edema, deep inter-phalangeal creases, small dysplastic nails and wide calibre veins.
(E) Comparison of lower limb lymphoscintigraphy at 2 hours in patient MLCRD01 II-2 and an unaffected control, showing no significant main tract filling suggestive of initial lymphatic vessel dysfunction.

Figure 2. Location of the identified mutations in KIF11

Upper panel: Mutations indicated with respect to the genomic organisation of the KIF11 gene.
Lower panel: KIF11 protein domain structure excluding the two identified splice site mutations.
Table 1. Clinical and genetic findings in *KIF11* mutation positive patients.

<table>
<thead>
<tr>
<th>Pedigree</th>
<th>ID</th>
<th>Gender</th>
<th>Head Circumference</th>
<th>Lymphedema</th>
<th>Eye abnormalities</th>
<th>Additional clinical features</th>
<th>Nucleotide variant</th>
<th>Exon</th>
<th>Protein alteration</th>
</tr>
</thead>
<tbody>
<tr>
<td>MLCRD01</td>
<td>I-1</td>
<td>Male</td>
<td>-3.0</td>
<td>minimal edema</td>
<td>none</td>
<td>mild LD</td>
<td>c.1159C&gt;T</td>
<td>10</td>
<td>p.R387X</td>
</tr>
<tr>
<td></td>
<td>II-2</td>
<td>Female</td>
<td>-7.2</td>
<td>congenital, bilateral, lower limb</td>
<td>none</td>
<td>mild LD, dysmorphic features</td>
<td>c.1159C&gt;T</td>
<td>10</td>
<td>p.R387X</td>
</tr>
<tr>
<td>MLCRD02</td>
<td>I-1</td>
<td>Female</td>
<td>-1.6</td>
<td>none</td>
<td>diabetic retinopathy</td>
<td>mild LD</td>
<td>c.3016delIA</td>
<td>21</td>
<td>p.I1006LfsX62</td>
</tr>
<tr>
<td></td>
<td>II-2</td>
<td>Female</td>
<td>-4.0</td>
<td>congenital, bilateral, lower limb</td>
<td>none</td>
<td>mild dysmorphic features</td>
<td>c.3016delIA</td>
<td>21</td>
<td>p.I1006LfsX62</td>
</tr>
<tr>
<td>MLCRD03</td>
<td>I-1</td>
<td>Male</td>
<td>-2.0</td>
<td>none</td>
<td>hypermetropic astigmatism, chorioretinopathy</td>
<td>mild LD</td>
<td>c.1039_1040delICT</td>
<td>9</td>
<td>p.L347fsX8</td>
</tr>
<tr>
<td></td>
<td>II-1</td>
<td>Male</td>
<td>-7.5</td>
<td>congenital, bilateral, lower limb plus pleural effusions</td>
<td>hypermetropic astigmatism, chorioretinopathy</td>
<td>mild LD</td>
<td>c.1039_1040delICT</td>
<td>9</td>
<td>p.L347fsX8</td>
</tr>
<tr>
<td></td>
<td>III-2</td>
<td>Female</td>
<td>-4.3</td>
<td>congenital, bilateral, lower limb</td>
<td>none</td>
<td>low birth weight, failure to thrive</td>
<td>c.432T&gt;G</td>
<td>5</td>
<td>p.F144L</td>
</tr>
<tr>
<td>MLCRD06</td>
<td>I-1</td>
<td>Male</td>
<td>-2.3</td>
<td>congenital, bilateral, lower limb</td>
<td>none</td>
<td>bilateral chorioretinopathy</td>
<td>c.2830C&gt;T (de novo)</td>
<td>20</td>
<td>p.R944C</td>
</tr>
<tr>
<td>MLCRD07</td>
<td>I-1</td>
<td>Male</td>
<td>-3.5</td>
<td>congenital, bilateral, lower limb</td>
<td>none</td>
<td>bilateral chorioretinopathy</td>
<td>c.1425_1426delinsAAA</td>
<td>12</td>
<td>p.V476NfsX2</td>
</tr>
<tr>
<td></td>
<td>II-1</td>
<td>Male</td>
<td>-5.5</td>
<td>congenital, mild, bilateral, lower limb</td>
<td>myopia</td>
<td>moderate LD</td>
<td>c.1425_1426delinsAAA</td>
<td>12</td>
<td>p.V476NfsX2</td>
</tr>
<tr>
<td>MLCRD08</td>
<td>I-1</td>
<td>Male</td>
<td>-3.0</td>
<td>none</td>
<td>none</td>
<td>mild LD, ASD, myoclonic epilepsy</td>
<td>c.1425_1426delinsAAA</td>
<td>13</td>
<td>p.Q531RfsX8</td>
</tr>
<tr>
<td></td>
<td>II-1</td>
<td>Male</td>
<td>-4.0</td>
<td>congenital, bilateral, lower limb</td>
<td>bilateral chorioretinopathy</td>
<td>mild LD, dysmorphic features</td>
<td>c.1526delIA</td>
<td>13</td>
<td>p.Q531RfsX8</td>
</tr>
<tr>
<td>MLCRD10</td>
<td>I-1</td>
<td>Male</td>
<td>-5.5</td>
<td>congenital, mild, bilateral, lower limb mild (resolved)</td>
<td>bilateral chorioretinopathy</td>
<td>mild LD</td>
<td>c.699-2A&gt;G(de novo)</td>
<td>6/7</td>
<td>acceptor splice site</td>
</tr>
<tr>
<td>MLCRD11</td>
<td>I-1</td>
<td>Male</td>
<td>low by history</td>
<td>congenital, bilateral, lower limb plus mild in hands</td>
<td>none</td>
<td>mild LD</td>
<td>c.2547+2T&gt;C</td>
<td>18/19</td>
<td>donor splice site</td>
</tr>
<tr>
<td></td>
<td>III-2</td>
<td>Male</td>
<td>-4.7</td>
<td>none</td>
<td>mild LD</td>
<td>c.2547+2T&gt;C</td>
<td>18/19</td>
<td>donor splice site</td>
<td></td>
</tr>
<tr>
<td></td>
<td>IV-1</td>
<td>Male</td>
<td>-4.0</td>
<td>congenital, bilateral, lower limb plus mild in hands</td>
<td>none</td>
<td>moderate LD, hypospadias</td>
<td>c.2547+2T&gt;C</td>
<td>18/19</td>
<td>donor splice site</td>
</tr>
<tr>
<td></td>
<td>IV-3</td>
<td>Male</td>
<td>-3.7</td>
<td>congenital, mild, bilateral, lower limb</td>
<td>none</td>
<td>moderate LD</td>
<td>c.2547+2T&gt;C</td>
<td>18/19</td>
<td>donor splice site</td>
</tr>
<tr>
<td></td>
<td>IV-5</td>
<td>Male</td>
<td>-4.1</td>
<td>none</td>
<td>mild LD</td>
<td>c.2547+2T&gt;C</td>
<td>18/19</td>
<td>donor splice site</td>
<td></td>
</tr>
<tr>
<td>MLCRD12</td>
<td>I-1</td>
<td>Male</td>
<td>-6.4</td>
<td>congenital, mild, bilateral, lower limb</td>
<td>bilateral chorioretinopathy</td>
<td>moderate LD</td>
<td>c.1963_1964dupAA</td>
<td>15</td>
<td>H6565X8</td>
</tr>
<tr>
<td>CDMMR01</td>
<td>I-1</td>
<td>Female</td>
<td>-5.0</td>
<td>adult onset, post traumatic mild edema,</td>
<td>chorioretinopathy</td>
<td>mild LD</td>
<td>c.1159C&gt;T(de novo)</td>
<td>10</td>
<td>p.R387X</td>
</tr>
<tr>
<td></td>
<td>III-1</td>
<td>Male</td>
<td>-5.5</td>
<td>none</td>
<td>hypermetropic astigmatism, chorioretinopathy</td>
<td>moderate LD</td>
<td>c.1159C&gt;T</td>
<td>10</td>
<td>p.R387X</td>
</tr>
<tr>
<td>CDMMR02</td>
<td>I-1</td>
<td>Female</td>
<td>low by history</td>
<td>none</td>
<td>bilateral chorioretinopathy</td>
<td>none</td>
<td>c.704C&gt;G</td>
<td>7</td>
<td>p.S235C</td>
</tr>
<tr>
<td></td>
<td>II-1</td>
<td>Female</td>
<td>low by history</td>
<td>none</td>
<td>bilateral chorioretinopathy</td>
<td>none</td>
<td>c.704C&gt;G</td>
<td>7</td>
<td>p.S235C</td>
</tr>
<tr>
<td>CDMMR03</td>
<td>I-1</td>
<td>Male</td>
<td>-3.4</td>
<td>none</td>
<td>no vision in right eye (retinal detachment), peripheral retinal atrophy in left eye</td>
<td>mild LD</td>
<td>c.2304_2305delCA (de novo)</td>
<td>18</td>
<td>p.H768RfsX7</td>
</tr>
<tr>
<td>CDMMR04</td>
<td>I-1</td>
<td>Male</td>
<td>-5.1</td>
<td>none</td>
<td>bilateral chorioretinopathy, nystagmus, exotropia</td>
<td>moderate LD</td>
<td>c.700C&gt;T</td>
<td>7</td>
<td>p.R234C</td>
</tr>
<tr>
<td>CDMMR05</td>
<td>I-1</td>
<td>Female</td>
<td>-3.9</td>
<td>none</td>
<td>bilateral chorioretinopathy</td>
<td>mild LD</td>
<td>c.1804C&gt;T</td>
<td>14</td>
<td>Q602X</td>
</tr>
<tr>
<td></td>
<td>II-2</td>
<td>Female</td>
<td>-2.6</td>
<td>none</td>
<td>hypermetropic astigmatism</td>
<td>none</td>
<td>c.1804C&gt;T</td>
<td>14</td>
<td>Q602X</td>
</tr>
</tbody>
</table>

MLCRD - microcephaly lymphedema chorioretinal dysplasia syndrome, CDMMR - chorioretinal dysplasia microcephaly mental retardation, LD - learning difficulties, ASD - atrial septal defect.

4 Individuals exome sequenced in primary analysis.

5 Case description in Vasudevan et al (2005).4


Head circumference measured as occipitofrontal head circumference and corrected for age and sex.
Figure 1